Press Releases – Sweden

February 20, 2018

Immune Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders and Provides Business Update

5 of 6 proposals pass with shareholder approval Meeting adjourned solely with respect to Proposal 4 – Ratification of the Reverse Stock Split Company outlines key corporate and clinical milestones for 2018  Englewood Cliffs, NJ (February 20, 2018) – Immune Pharmaceuticals, Inc. (NASDAQ FIRST NORTH; IMNP) (“Immune” or the “Company”) a biopharmaceutical company developing novel […]

Keep Reading

February 8, 2018

Immune Pharmaceuticals to be Delisted from Nasdaq Stockholm

Immune Pharmaceuticals Inc. (NASDAQ First North: IMNP) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases (the “Company”) announced today that the Disciplinary Board of Nasdaq Stockholm has decided to delist the Company’s shares. Trading of the Company’s shares on Nasdaq First North will be discontinued on March 29, […]

Keep Reading

February 6, 2018

Immune Pharmaceuticals to Present at the BIO CEO & Investor Conference on February 12, 2018

Englewood Cliffs, NJ- February 6, 2018 – Immune Pharmaceuticals Inc. (NASDAQ First North: IMNP) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced that its CEO, Elliot Maza, will present at the BIO CEO & Investor Conference, to be held February 12-13 at the New York Marriott Marquis in […]

Keep Reading

January 26, 2018

Immune Pharmaceuticals Announces Adjournment of Annual Meeting

Annual Meeting to Resume Thursday, February 15, 2018 Englewood Cliffs, NJ – January 26, 2018 – Immune Pharmaceuticals Inc. (NASDAQ First North: IMNP), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced today that it adjourned its Annual Meeting of Stockholders, scheduled for and convened on January 25, […]

Keep Reading

January 23, 2018

Immune Pharmaceuticals to Present at the NobleCon 14 Annual Investor Conference on January 30, 2018

Englewood Cliffs, New Jersey, USA- January 23, 2018 – Immune Pharmaceuticals Inc. (NASDAQ First North: IMNP) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced that its CEO, Elliot Maza, will present at NobleCon14- Noble Capital Markets’ Fourteenth Annual Investor Conference, to be held January 29-30 at the […]

Keep Reading

January 10, 2018

Immune Pharmaceuticals Announces Acceptance of Late-Breaking Abstract at the American Academy of Dermatology Annual Meeting 2018

Oral Presentation to Include Positive Interim Results from its Ongoing Phase 2 Trial of Bertilimumab in Bullous Pemphigoid Englewood Cliffs, New Jersey, USA – January 10, 2018 – Immune Pharmaceuticals Inc. (NASDAQ: IMNP) (the “Company”) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced today that an abstract […]

Keep Reading

January 4, 2018

Immune Pharmaceuticals to Present at the Biotech Showcase™ Annual Conference on January 10, 2018

Englewood Cliffs, New Jersey, USA – January 8, 2018 – Immune Pharmaceuticals Inc. (NASDAQ: IMNP), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced that it will present at Biotech Showcase ™ 2018, to be held January 8–10 during the most important week in healthcare investment forums at […]

Keep Reading

December 14, 2017

Immune Pharmaceuticals Announces Change in Certifying Accountant

Englewood Cliffs, NJ, USA – December 14, 2017 – Immune Pharmaceuticals Inc. (NASDAQ First North: IMNP) (the “Company”) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced that the Audit Committee of the Company notified BDO USA, LLP (“BDO”) the Company’s independent registered public accounting firm for the […]

Keep Reading